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Synthesis of novel N-protected hydrophobic 
phenylalanines and their application in potential 
antibacterials 
Timothy P. Boyle,a John B. Bremner,*a Jonathan A. Coates,b John Deadman,b Paul A. 
Keller,*a Stephen G. Pyne* a and Kittiya Somphola 
aSchool of Chemistry, University of Wollongong, Wollongong, NSW 2522 Australia. Fax:  
bAvexa Ltd, 576 Swan St, Richmond, Vic 3121 Australia.  
*Corresponding authors: Tel: Tel: +61 2 4221 3509; fax: +61 2 4221 4287  
E-mail address: keller@uow.edu.au or spyne@uow.edu.au 
Abstract:  An efficient synthesis of two new N-acetyl-4’-arylphenylalanines is described 
together with their incorporation in to a number of cationic peptoid antibacterial agents, 
one of which had an MIC of 7.8 μg/mL against Staphylococcus aureus. 








With the increasing spread of antibacterial resistance,1-3 including resistance by 
pathogenic bacteria to vancomycin,4,5 there is a compelling imperative for new 
antibacterials.6,7 In this context, we have undertaken a program investigating the design 
and synthesis of cyclic cationic peptoids linked by a hydrophobic scaffold as potential 
antibacterial agents, and thus far, have shown the binaphthyl8 and carbazole scaffolds9,10 
within these cyclic peptoids produce antibacterial agents, whilst the smaller indole based 
cyclic peptoids11 failed to inhibit bacterial growth. Therefore, as part of this program 
targeting new peptoid derivatives as antibacterial agents and attempting to address the 
resistance mechanism against vancomycin, we investigated the synthesis of novel 
hydrophobic amino acids and their subsequent incorporation into acyclic cationic 
peptides. These peptides were designed to further explore the effect of hydrophobicity 
and the role of cationic residues within the peptide. The synthesis and methodology of the 
novel hydrophobic amino acids, their incorporation into cationic peptides and aspects of 
their in vitro antibacterial activity are reported in this paper.12 
 
2. Chemistry 
The strategy employed to prepare the two hydrophobic amino acids preceded via a 
common trimethylstannyl amido acid 5, which was prepared from phenylalanine in four 
steps (Scheme 1). This common intermediate was then coupled to either 9-
bromoanthracene or 9-bromophenanthrene via a Stille coupling13 protocol followed by 
subsequent saponification to yield the hydrophobic amido acids 7a and 7b (Scheme 1). 
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Therefore, iodination of phenylalanine was performed as previously described14 to 
produce p-iodophenylalanine 2, which was isolated in quantitative yield. Esterification of 
2 with MeOH/SOCl2 afforded the methyl ester 3 as the hydrochloride salt in excellent 
yield, which was carried forward to the N-acetyl derivative 4 without further purification 
(Scheme 1). The key trimethylstannyl intermediate 5 was prepared following the 
procedure of Morera et al.,15 in 76% yield. This methodology was favoured over 
previously reported methods,16 due to the faster reaction time in preparing the 
aryltrimethylstannane over the aryltributylstannane, significantly decreasing the 
possibility of racemization at the  position of the amido ester.  
The hydrophobic amido esters 6a and 6b, were prepared via a Stille coupling 
methodology14,15 in 67% and 59% yields, respectively (Scheme 1). The ligand of choice 
for this reaction was tri-o-tolylphosphine, as phenyl transfer to the amino acid was 
observed when triphenylphosphine was present as the ligand. It was also found that 
increasing the temperature above 85 oC resulted in faster reaction times and also resulted 
in partial racemization of the -stereocentre of the amido ester. However, at 70 oC, no 
racemization was observed. Partial racemization of these products formed at the higher 
temperature was detected from 1H NMR analysis of their products 12a,b (Scheme 2) that 
showed NMR signals for a minor diastereomer.  The desired free acid form was obtained 





























a. Ar = 9-anthracenyl














Reagents and conditions: (a) NaIO3, AcOH, H2SO4, 70 
oC, 16 h, 100% (b) SOCl2, 
MeOH, 0 oC – RT, 16 h, 99% (c) Ac2O, AcONa(aq), 0 
oC, 56% (d) (SnMe3)2, Pd(OAc)2, 
PPh3, PhMe, 100 
oC, 30 min, 76% (e) a, 9-bromoanthracene, Pd(OAc)2, P(o-tol)3, DMF, 
70 oC, 16 h, 6a: 67%; b. 9-bromophenanthrene, Pd(OAc)2, P(o-tol)3, DMF, 70 
oC, 16 h, 




The peptide fragment 10 was prepared employing a well established EDCI peptide 
coupling methodology and a Fmoc protection/deprotection protocol.8-11 This fragment 
was coupled to 7a and 7b to give the protected tripeptoids 11a and 11b, respectively 
(Scheme 2).  N-Boc deprotection of 11a and 11b by exposure to TFA, followed by anion 
exchange with HCl provided the hydrochloride salts 12a and 12b, respectively (Scheme 
2).  














































a. Ar = 9-anthracenyl






Reagents and conditions: (a) Fmoc-L-lysine(Boc)OH, EDCI, HOBt, CH2Cl2, DMAP, RT, 
16 h, 87%. (b) 1% Piperidine, MeCN, RT, 3 h, 100% (c) 7a, EDCI, HOBt, DMF, RT, 16 




This chemistry was further expanded to include the dicationic tetrapeptoids 20a and 20b, 
that also incorporated the hydrophobic amido acids 7a,b and the less hydrophobic O-
allyltyrosine peptoid analogue 20c (Scheme 3).  Allyl glycine 13 was converted to its 
benzyl ester 14 which was coupled to Fmoc-D-arginine(Pmc)OH to give the dipeptide 15.  
Selective base catalysed removal of the N-Fmoc protecting group of 15 gave the free 
amine 16 that was coupled to Fmoc-D-lysine(Boc)OH to give the protected tripeptoid 17.  
N-Fmoc removal from 17 and coupling of the resulting amine 18 with 7a or 7b gave the 
protected tetrapeptoids 19a and 19b, respectively.  Coupling of 18 with N-acetyl-O-allyl-
L-tyrosine17 gave the tetrapeptoid 19c.  Acid catalysed deprotection of 19a, 19b and 19c, 
followed by anion exchange with HCl, gave the bis-hydrochloride salts of tetrapeptoids 















































































































a; R = 9-anthracenyl
b; R = 9-phenanthrenyl









Reagents and conditions: (a) BnOH, SOCl2, 16 h, RT, 68% (b) Fmoc-D-
arginine(Pmc)OH, EDCI. HOBt, DMF, 16 h, RT, 51%. (c) 1% Piperidine, MeCN, RT, 3 
h, 70%  (d) Fmoc-D-lysine(Boc)OH, EDCI. HOBt, DMF, 16 h, RT, 51%. (e) 1% 
 8
Piperidine, MeCN, RT, 3 h, 93% (f) 7a or 7b or N-Ac-O-allyl-L-tyrosine, EDCI. HOBt, 
DMF, 16 h, RT, 19a: 36%, 19b: 80%, 19c: 85% (g) TFA/CH2Cl2 (1 : 1), RT, 3 h, then 
HCl/ether, 20a: 88%, 20b: 79%, 20c: 85%. 
 
 
2.2. In vitro antibacterial activity 
The synthesized hydrophobic and cationic peptoids 12a, 12b, 20a, 20b and 20c were 
tested against the Gram-positive bacterium S. aureus (ATCC6538) and showed MIC 
values of 31.3, 15.6, 15.6, 7.8 and >125 g/mL, respectively.  The positive control, 
vancomycin, showed a MIC value of 1.95 g/mL. In stark contrast to 12a,b and 20a,b 
the less hydrophobic tetrapeptoid 20c was not active (MIC > 125 g/mL). The 9-
phenanthrenyl peptoids, 12b and 20b, were more active than their respective 9-
anthracenyl counterparts, 12a and 20a.  The dicationic peptoids, 20a,b were more active 
than their respective monocationic analogues 12a,b.  However it should be noted that 
peptides 12a,b have a L-lysine residue whereas the peptides 20a,b have a D-lysine 
residue. These differences limit further structure-activity comparisons to be made 
between the tripeptides 12a,b and tetrapeptides 20a,b. These biological results are 
consistent with the pharmacophore model proposed by Svendsen12 for peptide 
compounds which indicates that two hydrophobic and two cationic sites are important for 
antibacterial activity.  In our case the benzyl ester moiety in 20a,b would represent the 
second, albeit considerably smaller, hydrophobic group.   
In contrast to the activity shown against S aureus, the cationic peptoids 12a, 12b, 20a, 
and 20b, were not active against Enterococcus faecalis strains (both vancomycin 
sensitive and resistant strains); MIC values >125 µg/mL were obtained against these 






We have developed a useful method for preparing the novel biaryl hydrophobic amido 
acids 7a,b via Stille coupling reactions.  This method could potentially be employed to 
prepare other novel biaryl phenylalanine derivatives. We have shown that incorporation 
of these hydrophobic amido acid residues into cationic peptides resulted in peptoids 
having significant antibacterial activity against S. aureus when compared to a less 
hydrophobic, O-allyltyrosine analogue 20c. These results highlight the importance of 
hydrophobicity within the peptoid for antibacterial activity and provide a platform for 
further development of antimicrobial agents with improved activity against S. aureus.  
 
4. Experimental  
4.1. Chemistry 
Chemical Ionisation (CI) mass spectra were obtained on a Shimadzu QP-5000 mass 
spectrometer by a direct insertion technique (electron beam density 70 eV). Electrospray 
ionization (ESI) mass spectra were obtained on a VG Quattro spectrometer. High-
resolution mass spectra (HRMS) were determined on a VG Autospec spectrometer or on 
a micromass QTof2 spectrometer using polyethylene glycol as the internal standard. The 
m/z values are stated with their peak intensity percentages in parentheses. Optical 
rotations were measured using a Jasco DIP-370 digital polarimeter with a 10 mm path 
length. Proton and carbon nuclear magnetic resonance (NMR) spectra were determined in 
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CDCl3 solution at 300 MHz (
1H NMR) or 75 MHz (13C NMR) unless otherwise stated, 
using a Varian Mercury 300 MHz or Varian Inova 500 MHz spectrometer. TMS was 
used as the internal standard and all chemical shifts () were measured relative to the 
internal standard. Analytical thin layer chromatography (TLC) was carried out on Merck 
Silica gel 60 F254 pre-coated aluminium plates with a 0.2 mm adsorbant thickness. All 
column chromatography was performed under ‘flash’ conditions on Merck Silica gel 60 
(230-400 mesh). 1H NMR assignments were achieved with the aid of gCOSY, and in 
some cases NOESY and TOCSY experiments. 13C NMR assignments were based upon 
DEPT, gHSQC and sometimes gHMBC experiments. All compounds were homogeneous 
by TLC analysis and judged to be of >95% purity based upon 1H NMR analysis. 
Compound numbering is based on that of compound 20 as shown in Scheme 3. All 
compounds were judged to be greater than 95% purity based upon 1H NMR and TLC 
analysis. Solvent ratios are vol/vol. 
 
4.2 General Procedures 
4.2.1. General synthetic procedure for N-Boc and Pmc Deprotection (Procedure A) 
The N-Boc or Pmc protected amine was stirred for 3 h in 1 : 1 CH2Cl2/TFA (5 mL / 0.1 
mmol of substrate) solution at RT. The solvent was removed under reduced pressure, and 
the residue was resuspended in a minimal volume of methanol. The solution was then 
treated with an excess of 1M HCl/ether solution and the solvent evaporated. The crude 
product was purified by precipitation from CH2Cl2 and/or MeOH by addition of diethyl 
ether. 
4.2.2. General synthetic procedure for peptide coupling (Procedure B) 
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To a solution of the acid (1 equiv.) in DMF (10 mL per 1 mmol of substrate) at room 
temperature was added HOBt (1.1 equiv.), EDCI (1 equiv.) and the amine (1.2 equiv.). If 
the amine was a hydrochloride salt, DIPEA (1 equiv.) was also added. The mixture was 
allowed to stir for 16 h before dilution with EtOAc (30 mL) and washing with water (30 
mL) and brine (30 mL). The organic fraction was dried (MgSO4) and further purified by 
column chromatography if required. 
 
4.2.3. General synthetic procedure for N-Fmoc Deprotection (Procedure C) 
The Fmoc protected amine was stirred in 1% piperidine/acetonitrile (5 mL per 1 mmol of 
substrate) for 3 h at RT. The solvent was removed under reduced pressure and the crude 
product was purified by flash column chromatography (15:1, CH2Cl2/MeOH) to yield the 
free amine. 
 
4.2.4. (S)-2-Amino-3-(4-iodophenyl)propanoic acid 2 
To a solution (S)-2-amino-3-phenylpropanoic acid (4.01 g, 24.3 mmol) in acetic acid (22 
mL) was added sulfuric acid (2.9 mL, 5.14 mmol), iodine (2.47 g, 4.7 mmol) and sodium 
iodate (1.02 g, 5.14 mmol). The mixture was heated to 70 oC and allowed to stir at this 
temperature for 16 h before an additional portion of sodium iodate (1.02 g, 5.14 mmol) 
was added. The reaction was left for a further 2 h before being concentrated, dissolved in 
MeOH (20 mL) and treated with NaOH (60 mL). The mixture was left to precipitate out 
of the basic solution overnight and the resulting solid was filtered by vacuum filtration to 
yield the title compound 2 (7.07 g, 24.3 mmol, 100%) as a pink solid, which had spectral 
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data in agreement with that reported.14 []D21 –10.6 (c. 0.3, HCl). Mp 258-260 oC (lit. 
261-262 oC).14  
 
4.2.5. Methyl (2S)-2-amino-3-(4-iodophenyl)propanoate hydrochloride 3 
To a solution of 2 (2.00 g, 6.87 mmol) in MeOH (10 mL) at 0 oC was added thionyl 
chloride (2 mL) and the resulting solution was allowed to stir for 16 h whilst equilibrating 
to RT. The reaction was evaporated to dryness in vacuo to yield the title compound 3 
(2.25 g, 6.80 mmol, 99%) as a white solid, which had spectral data in agreement with that 
reported.14 []D21 -9.3 (c. 0.15, HCl). Mp 195-198oC (lit. 199.5-200.5oC).14   
 
4.2.6. Methyl (2S)-2-acetamido-3-(4-iodophenyl)propanoate 4 
To a solution of 3 (2.25 g, 6.80 mmol) in 10% HCl (10 mL) at 0 oC was added 4M 
sodium acetate (115 mL) and the resulting reaction was allowed to stir whilst 
equilibrating to 0 oC. Acetic anhydride (50 mL) was added and the reaction allowed to 
proceed with vigorous stirring. After 1 h the product was collected by vacuum filtration, 
dissolved in ethyl acetate (30 mL) and washed with 2M sodium bicarbonate (2 x 30 mL). 
The organic layer was dried and evaporated to yield the title compound 4 (1.31 g, 3.79 
mmol, 56%) as a white solid. Mp 118-120 oC. []D27 +93.8 (c. 0.1, CHCl3). 1H NMR 
(CDCl3, 300 MHz):  7.61 (d, J = 8.4 Hz, 2H, ArH2’ and ArH6’); 6.84 (d, J = 8.1 Hz, 2H, 
ArH3’ and ArH5’); 5.92 (d, J = 7.2 Hz, 1H, NH); 4.87 (m, 1H, H2); 3.73 (s, 3H, OCH3); 
3.11 (dd, J = 6.0, 13.8, Hz, 1H, H3a); 3.03 (dd, J = 5.4, 13.8 Hz, 1H, H3b); 1.99 (s, 3H, 
NCOCH3).
 13C NMR (CDCl3, 75 MHz):  171.8, C1; 169.5, NCO; 137.6, ArCH2’ and 
ArCH6’; 135.5, ArC4’; 131.2, ArCH3’ and ArCH5’; 94.1, ArC1’; 52.9, C2; 52.4, OCH3; 
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37.4, C3; 23.1, NCOCH3. Mass Spectrum (CI+) m/z 348 (100%) [MH
+]. HRMS calcd for 
C12H15NO3I 348.0097, found 348.0104. 
 
4.2.7. Methyl (2S)-2-acetamido-3-(4-trimethylstannylphenyl)propanoate 5 
A solution of 4 (590 mg, 1.7 mmol), hexamethyldistannane (781 mg, 2.38 mmol), 
palladium acetate (20 mg, 0.085 mmol), and triphenylphosphine (45 mg, 0.17 mmol) in 
toluene (7 mL) was flushed with nitrogen for 15 min and then heated at 100 oC for 30 
min under N2. The brown mixture was filtered through a short pad of silica, diluted with 
diethyl ether (40 mL) and washed twice with water. The organic layer was dried and 
evaporated to yield the title compound 5 (497 mg, 1.29 mmol, 76%) as a clear oil. []D27 
+13.7 (c. 0.3, CHCl3).
 1H NMR (CDCl3, 300 MHz):  7.41 (d, J = 7.5 Hz, 2H, ArH2’ and 
ArH6’); 7.07 (d, J = 7.8 Hz, 2H, ArH3’ and ArH5’); 6.25 (d, J = 7.8 Hz, 1H, NH); 4.87 
(m, 1H H2); 3.72 (s, 3H, OCH3); 3.12 (dd, J = 5.7, 14.1 Hz, 1H, H3a); 3.04 (dd, J = 6.0, 
13.9 Hz, 1H, H3b); 1.98 (s, 3H, NCOCH3); 0.27 (t, J = 27.6 Hz, 9H, Sn(CH3)3).
 13C NMR 
(CDCl3, 75 MHz):  172.1, C1; 169.7, NCO; 140.6, ArC4’; 135.9, ArCH2’ and ArCH6’; 
135.9, ArC1’; 128.7, ArCH3’ and ArCH5’; 53.0, C2; 52.1, OCH3; 37.5, C3; 23.9, 
NCOCH3; -9.7, Sn(CH3)3. Mass Spectrum (CI+) m/z 386 (50%) [MH
+], 382 (10%) 
[MH+] (112Sn), 85 (100%). HRMS calcd for C15H24NO3Sn (
112Sn) 382.0754 found 
382.0756. 
 
4.2.8.  Methyl (2S)-2-acetamido-3-(4-[9-anthracenyl]phenyl)-propanoate 6a 
A solution of 5 (192 mg, 0.50 mmol), 9-bromoanthracene (141 mg, 0.55 mmol), 
palladium acetate (6 mg, 0.025 mmol), and tri-o-tolylphosphine (15 mg, 0.05 mmol) in 
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DMF (2 mL) was flushed with N2 for 15 min then heated to 70 
oC and allowed to stir for 
16 h. The reaction was diluted with diethyl ether (20 mL) and washed with water (5 x 20 
mL), dried and evaporated. The crude product was purified by flash column 
chromatography (15% EtOAc/hexane then 5% MeOH/CH2Cl2) to yield the title 
compound 6a (133 mg, 0.33 mmol, 67%) as an orange oil. []D27 +66.9 (c. 0.1, CHCl3). 
1H NMR (CDCl3, 300 MHz):  8.48 (s, 1H, ArH10”); 8.03 (dd, J = 0.9, 8.7 Hz, 2H, 
ArH3” and ArH6”); 7.63 (dd, J = 0.6, 9.0 Hz, 2H, ArH8” and ArH1”); 7.45 (m, 2H, 
ArH4” and ArH5”); 7.36 (m, 6H, ArH2” and ArH7”, 4 x ArH’); 5.40 (d, J = 7.8 Hz, 1H, 
NH); 5.04 (m, 1H, H2); 3.79 (s, 3H, OCH3); 3.32 (dd, J = 5.7, 13.8 Hz, 1H, H3a); 3.25 
(dd, J = 6.3, 13.8 Hz, 1H, H3b); 2.08 (s, 3H, COCH3).
 13C NMR (CDCl3, 75 MHz):  
172.2, C1; 169.8, COCH3; 137.4, ArC9”; 136.4, ArC4’; 135.2, ArC1’; 132.0, ArC8a” and 
ArC9a”; 131.9, ArCH2” and ArCH7”; 131.3, ArCH2’ and ArCH6’; 129.2, ArCH3’ and 
ArCH5’; 128.3, ArCH4” and ArCH5”; 126.5, ArC4a” and ArC10a”; 125.3, ArCH8” and 
ArCH1”; 125.0, ArCH3” and ArCH6”, ArCH10”; 53.3, C2; 52.3, OCH3; 37.8, C3; 23.1, 
COCH3. Mass Spectrum (CI+) m/z 398 (100%) [MH
+]. HRMS calcd for C26H23NO3 
397.1678, found 397.1675. 
 
4.2.9. Methyl (2S)-2-acetamido-3-(4-[9-phenanthrenyl]phenyl)propanoate 6b 
A solution of 5 (259 mg, 0.67 mmol), 9-bromophenanthrene (190 mg, 0.74 mmol), 
palladium acetate (8 mg, 0.034 mmol), and tri-o-tolylphosphine (20 mg, 0.067 mmol) in 
DMF (2 mL) was flushed with N2 for 15 min then heated to 70 
oC and allowed to stir for 
16 h. The reaction was diluted with diethyl ether (20 mL) and washed with water (5 x 20 
mL), dried and evaporated. The crude product was purified by flash column 
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chromatography (15% EtOAc/hexane then 5% MeOH/CH2Cl2) to yield the title 
compound 6b (157 mg, 0.40 mmol, 59%) as a clear oil. []D27 +94.6 (c. 0.1, CHCl3). 1H 
NMR (CDCl3, 300 MHz):  8.77 (d, J = 9.0 Hz, 1H, ArH4”); 8.71 (d, J = 8.1 Hz, 1H, 
ArH3”); 7.89 (m, 2H, ArH1” and ArH10”); 7.61 (m, 5H, ArH7”, ArH6”, ArH5”, ArH2” 
and ArH1”); 7.48 (d, J = 8.4 Hz, 2H, ArH2’ and ArH6’); 7.26 (d, J = 8.1 Hz, 2H, ArH3’ 
and ArH5’); 6.25 (d, J = 7.5 Hz, 1H, NH); 5.00 (m, 1H, H2); 3.79 (s, 3H, OCH3); 3.30 
(dd, J = 5.7, 13.8 Hz, 1H, H3a); 3.20 (dd, J = 6.0, 13.8 Hz, 1H, H3b); 2.05 (s, 3H, 
COCH3).
 13C NMR (CDCl3, 75 MHz):  172.1, C1; 169.7, COCH3; 139.5, ArC4’; 138.2, 
ArC1’; 135.0, ArC9”; 131.4, ArC4b”; 130.9, ArC9a”; 130.6, ArC4a”; 130.1, ArCH2’ and 
ArCH6’; 129.9, ArC10a”; 129.1, ArCH3’ and ArCH5’; 128.5, ArCH1”; 127.4, ArCH7”; 
126.8, ArCH6”; 126.7, ArCH1”; 126.5, ArCH5”; 126.4, ArCH10”; 126.3, ArCH2”; 
122.9, ArCH4”; 122.4, ArCH3”; 53.2, C2; 52.3, OCH3; 37.6, C3; 23.0, COCH3. Mass 
Spectrum (CI+) m/z 398 (100%) [MH+]. HRMS (EI) calcd for C26H23NO3 397.1678, 
found 397.1680. 
 
4.2.10. (2S)-2-Acetamido-3-(4-[9-anthracenyl]phenyl)propanoic acid 7a 
To a solution of 6a (80 mg, 0.20 mmol) in THF/water, 2:1 (3 mL) was added lithium 
hydroxide monohydrate (17 mg, 0.40 mmol) and the resulting suspension was allowed to 
stir for 16 h. The reaction mixture was diluted with water (30 mL) and the THF was 
removed by evaporation. The aqueous layer was washed with CH2Cl2 (40 mL) to remove 
unreacted starting material. The aqueous phase was acidified with 10% HCl and the 
resulting precipitate was extracted with CH2Cl2 (3 x 40 mL). The combined organics 
were dried and evaporated to yield the title compound 7a (69 mg, 0.18 mmol, 90%) as a 
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white solid. Mp 76 oC. []D20 +29.7 (c. 0.1, EtOH). 1H NMR (CDCl3, 300 MHz):  8.47 
(s, 1H, ArH10”); 8.02 (d, J = 8.4 Hz, 2H, ArH3” and ArH6”); 7.59 (d, J = 8.7 Hz, 2H, 
ArH8” and ArH1”); 7.45 (m, 2H, ArH4” and ArH5”); 7.35 (m, 6H, ArH2” and ArH7”, 4 
x ArH’); 6.27 (d, J = 6.6 Hz, 1H, NH); 5.00 (m, 1H, H2); 3.39 (dd, J = 4.8, 12.9 Hz, 1H, 
H3a); 3.26 (dd, J = 6.3, 14.4 Hz, 1H, H3b); 2.07 (s, 3H, COCH3).
 13C NMR (CDCl3, 75 
MHz):  174.2, C1; 171.2, COCH3; 137.5, ArC9”; 136.4, ArC4’; 135.0, ArC1’; 131.4, 
ArC8a”; 131.2, ArC9a”; 130.1, ArCH2” and ArCH7”; 129.3, ArCH2’ and ArCH6’; 
128.8, ArCH3’ and ArCH5’; 128.3, ArCH4” and ArCH5”; 126.6, ArC4a” and ArC10a”; 
125.3, ArCH8” and ArCH1”; 125.0, ArCH3” and ArCH6”, ArC10”; 53.5, C2; 37.3, C3; 
22.9, COCH3. Mass Spectrum (ESI+) m/z 383 (70%) [MH
+]. HRMS calcd for C25H22NO3 
384.1600, found 384.1610. 
 
4.2.11. (2S)-2-Acetamido-3-(4-[9-phenanthrenyl]phenyl)propanoic acid 7b 
To a solution of 6b (124 mg, 0.31 mmol) in THF/water, 2:1 (9 mL) was added lithium 
hydroxide monohydrate (26 mg, 0.62 mmol) and the resulting suspension was allowed to 
stir for 16 h. The reaction mixture was diluted with water (30 mL) and the THF was 
removed by evaporation. The aqueous layer was washed with CH2Cl2 (40 mL) to remove 
unreacted starting material. The aqueous phase was acidified with 10% HCl and the 
resulting precipitate was extracted with CH2Cl2 (3 x 40 mL). The combined organics 
were dried and evaporated to yield the title compound 7b (65 mg, 0.17 mmol, 55%) as a 
white solid. Mp 128-132 oC. []D20 +36.8 (c. 0.1, EtOH). 1H NMR (CD3OD, 300 MHz):  
8.71 (d, J = 8.1 Hz, 1H, ArH4”); 8.66 (d, J = 8.4 Hz, 1H, ArH3”); 7.79 (s, 1H, ArH1”); 
7.76 (s, 1H, ArH10”); 7.51 (m, 5H, ArH7”, ArH6”, ArH5”, ArH2” and ArH1”); 7.32 (m, 
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2H, Ar’H); 4.76 (dd, J = 5.1, 9.0 Hz, 1H, H2); 3.29 (dd, J = 4.8, 13.5 Hz, 1H, H3a); 3.03 
(dd, J = 8.7, 13.5 Hz, 1H, H3b); 1.95 (s, 3H, COCH3).
 13C NMR (CD3OD, 75 MHz):  
174.8, C1; 173.2, COCH3; 140.5, ArC4’; 139.7, ArC1’; 137.7, ArC9”; 132.9, ArC4b”; 
132.2, ArC8a”; 131.9, ArC4a”; 131.2, ArC10a”; 131.1, ArCH2’ and ArCH6’; 130.2, 
ArCH3’ and ArCH5’; 129.6, ArCH1”; 128.3, ArCH3”; 127.9, ArCH6”; 127.7, ArCH1”; 
127.7, ArCH5”; 127.6, ArCH10”; 127.5, ArCH2”; 124.0, ArCH4”; 123.5, ArCH3”; 55.2, 
C2; 38.2, C3; 22.4, COCH3. Mass Spectrum (ESI+) m/z 384 (50%) [MH
+]. HRMS calcd 




To a solution of 818 (430 mg, 2.61 mmol) and Fmoc-L-lysine(Boc)OH (1.22 g, 2.61 
mmol) in CH2Cl2 (10 mL) was added EDCI (500 mg, 2.61 mmol) and a catalytic quantity 
of DMAP. The resulting mixture was allowed to stir at RT for 16 h. The reaction was 
diluted with CH2Cl2 (25 mL), then the organic layer was washed with brine (2 x 25 mL) 
and water (2 x 25 mL) and dried, before being concentrated. The crude product was 
purified by flash column chromatography (25:1 CH2Cl2/ MeOH) to afford the title 
compound (1.31 g, 2.27 mmol, 87%) as a cream coloured solid. Mp 123-126 oC. 1H NMR 
(CDCl3, 300 MHz):  7.76 (d, J = 7.6 Hz, 2H, ArH1” and ArH8”); 7.59 (d, J = 7.6 Hz, 
2H, ArH4” and ArH5”); 7.40 (t, J = 7.6 Hz, 2H, ArH3” and ArH6”); 7.31 (ddd, J = 9.0, 
7.2, 1.2 Hz, 2H, ArH2” and ArH7”); 6.46 (bs, 1H, NH); 5.64 (m, 1H, H2’); 5.44 (s, 1H, 
NH); 5.10 (m, 2H, H3’); 4.65 (m, 1H, H2); 4.39 (d, J = 7.2 Hz, 2H, OCH2-H9”); 4.22 (m, 
1H, H5); 4.17 (bs, 1H, H9”); 3.74 (s, 3H, OCH3); 3.11 (m, 2H, H9); 2.55 (m, 2H, H1’); 
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1.85 (m, 2H, H7); 1.65 (m, 2H, H6); 1.50 (m 2H, H8); 1.44 (s, 9H, C(CH3)3).
 13C NMR 
(CDCl3, 75 MHz):  171.9, C4; 171.6, C1; 156.2, NCO2; 143.7, ArC8a” and ArC9a”; 
142.7, ArC4a” and ArC4b”; 131.9, C2’; 127.7, ArCH3” and ArCH6”; 127.0, ArCH2” 
and ArCH7”; 125.0, ArCH1” and ArCH8”; 119.9, C3’; 119.3, ArCH4” and ArCH5”; 
79.1, C(CH3)3; 67.0, CH2-C9”; 54.5, C5; 52.4, OCH3; 50.6, C2; 47.0, C9”; 39.8, C9; 
36.1, C1’; 32.0, C6; 29.9, C8; 28.3, C(CH3)3; 22.2, C7. Mass Spectrum (ESI+) m/z 580.5 
(10%) [MH+], 130.5 (100%) [MH+ (less allylgly)]. HRMS calcd for C32H42N3O7 




The title compound was synthesized using the general N-Fmoc deprotection procedure 
(Procedure C), from 9 (1.27 g, 2.19 mmol) to yield 10 (778 mg, 2.18 mmol, 100%) as a 
cream oil. 1H NMR (CDCl3, 300 MHz):  7.81 (d, J = 8.0 Hz, 1H, NH); 5.69 (m, 1H, 
H2’); 5.11 (m, 2H, H3’); 4.76 (bs, 1H, NH); 4.67 (m, 1H, H2); 3.75 (s, 3H, OCH3); 3.39 
(dd, J = 4.6, 7.6 Hz, 1H, H5); 3.12 (d, J = 6.3 Hz, 2H, H9); 2.54 (m, 2H, H1’); 1.52 (m, 
8H, H6, H7, H8 and NH2); 1.44 (s, 9H, C(CH3)3).
 13C NMR (CDCl3, 75 MHz):  174.8, 
C4; 172.1, C1; 156.0, NCO2; 132.2, C2’; 118.9, C3’; 78.9, C(CH3)3; 54.8, C5; 52.2, C2; 
51.1, OCH3; 40.0, C9; 36.4, C1’; 34.4, C6; 29.7, C8; 28.3, C(CH3)3; 22.6, C7. Mass 
Spectrum (ESI+) m/z 358.5 (85%) [MH+], 258.4 (100%) [MH+ (less Boc)]. HRMS calcd 
for C17H32N3O5 358.2342, found 358.2339. 
 
4.2.14. Benzyl (2S)-2-amino-4-pentenoate hydrochloride 14 
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To a solution of 13 (225 mg, 1.96 mmol) in benzyl alcohol (5 mL) was added thionyl 
chloride (2 mL) and the resulting mixture was allowed to stir for 16 h before addition of 
diethyl ether (30 mL) and extraction with water (3 x 30 mL). The aqueous layer was 
concentrated, diluted with 2M sodium bicarbonate (20 mL), and extracted with CH2Cl2 (3 
x 30 mL). The combined organic fractions were dried and acidified with 1M HCl/diethyl 
ether (2 mL) and evaporated. The crude product dissolved in a minimal volume of MeOH 
and precipitated with diethyl ether to yield the title compound (322 mg, 1.34 mmol, 68%) 
as a white solid. []D20 – 40.6 (c. 0.1, H2O). Mp 186-191 oC.  1H NMR (D2O, 300 MHz): 
7.28 (m, 5H, ArH); 5.51 (m, 1H, H4); 5.11 (m, 4H, H5 and ArCH2); 4.08 (t, J = 5.4 Hz, 
1H, H2); 2.55 (m, 2H, H3). 13C NMR (D2O, 75 MHz): 172.1, C1; 137.3, C4; 132.5, 
ArC1’; 131.7, ArC4’; 131.6, ArCH’; 131.4, ArCH’; 124.4, C5; 71.3, ArCH2; 54.9, C2; 
36.8, C3. Mass Spectrum (CI+) m/z 205 (25%) [MH+]. HRMS calcd for C12H16NO2 




The title compound was synthesised using the general peptide coupling procedure 
(Procedure B), from 14 (155 mg, 0.65 mmol) and Fmoc-D-arginine(Pmc)OH (431 mg, 
0.65 mmol) to afford 15 (280 mg, 0.33 mmol, 51%) as a white solid. Mp 78-74 oC. 1H 
NMR (CDCl3, 300 MHz):  7.69 (d, J = 7.5 Hz, 2H, ArH1” and ArH8”); 7.51 (d, J = 7.5 
Hz, 2H, ArH4” and ArH5”); 7.28 (m, 9H, ArH); 6.33 (m, 3H, NH); 5.68 (m, 1H, H2’); 
5.61 (m, 1H, NH); 4.99 (m, 4H, ArCH2 and H3’); 4.58 (m, 1H, H2); 4.24 (m, 3H, OCH2-
H9”and H5); 4.05 (dd, J = 7.2, 7.2 Hz, 1H, H9”); 3.20 (m, 2H, H8); 2.57 (s, 3H, 7”’-
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CH3); 2.54 (s, 3H, 5”’-CH3); 2.52 (m, 4H, H3”’ and H1’); 2.05 (s, 3H, 8”’-CH3); 1.85 (m, 
2H, H6); 1.69 (dd, J = 6.3, 6.3 Hz, H4”’); 1.58 (m, 2H, H7); 1.22 (s, 6H, 2 x 2”’-CH3).
 
13C NMR (CDCl3, 75 MHz):  172.2, C1; 171.4, C4; 156.4, ArC6”’; 156.3, NCO2; 153.5, 
ArC8a”’; 143.7, CN3; 143.6, ArC8a” and ArC9a”; 141.0, ArC4a” and ArC4b”; 135.3, 
ArC7”’; 135.1, ArC5”’; 134.8, C2’; 128.5, ArC; 128.4, ArC; 128.3, ArC; 128.2, ArC; 
127.6, ArCH2” and ArCH7”; 127.0, ArCH3” and ArCH6”; 125.1, ArCH4” and ArCH5”; 
124.0, ArC8”’; 119.8, ArCH1” and ArCH8”; 119.0, C3’; 117.9, ArC4a”’; 73.5, C2”’; 
67.0, ArCH2; 66.7, CH2-C9”; 54.7, C5; 53.8; 53.4, C2; 46.8, C9”; 39.0, C8; 35.7, C1’; 
32.6, C4”’; 29.8, C6; 26.6, 2”-CH3; 22.4, C7; 21.3, C3”’; 18.5, C7”’-CH3; 17.5, C5”’-
CH3; 12.0, C8”’-CH3. Mass Spectrum (ESI+) m/z 850 (100%) [MH
+]. HRMS calcd for 




The title compound was synthesized using the general N-Fmoc deprotection procedure 
(Procedure C), from 15 (278 mg, 0.33 mmol) to yield 16 (144 mg, 0.23 mmol, 70%) as a 
cream semi-solid. Mp 66-68 oC.  1H NMR (CDCl3, 300 MHz):  7.85 (d, J = 7.8 Hz, 1H, 
NH); 7.60 (d, J = 7.8 Hz, 1H, NH); 7.32 (m, 5H, ArH); 6.33 (m, 2H, NH2); 5.63 (s, 1H, 
H2’); 5.14 (m, 4H, ArCH2 and H3’); 4.56 (m, 1H, H2); 3.40 (m, 1H, H5); 3.16 (m, 2H, 
H8); 3.09 (m, 2H, H1’); 2.61 (t, J = 6.9 Hz, 2H, H4”); 2.56 (s, 3H, 7”-CH3); 2.55 (s, 3H, 
5”-CH3); 2.09 (s, 3H, 8”-CH3); 1.78 (t, J = 7.2 Hz, 2H, H3”); 1.68 (m, 4H, H6 and NH2); 
1.54 (m, 2H, H7); 1.29 (s, 6H, 2 x 2”-CH3).
 13C NMR (CDCl3, 75 MHz):  171.4, C1; 
171.2, C4; 156.2, ArC6”; 153.4, ArC8a”; 146.0, CN3; 135.2, ArC7”; 135.1, ArC5”; 
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134.7, C2’; 128.5, ArC; 128.3, ArC; 128.3, ArC; 128.2, ArC; 123.9, ArC8”; 119.2, C3’; 
117.8, ArC4a”; 73.5, C2”; 67.1, ArCH2; 54.2, C5; 53.4, C2; 40.8, C8; 35.9, C1’; 32.7, 
C4”; 30.8, C6; 29.3, C7; 26.6, 2”-CH3; 21.3, C3”; 18.4, C7”-CH3; 17.4, C5”-CH3; 12.0, 
C8”-CH3. Mass Spectrum (ESI+) m/z 628 (100%) [MH
+]. HRMS calcd for C32H46N5O6S 





The title compound was synthesised using the general peptide coupling procedure 
(Procedure B), from 16 (200 mg, 0.32 mmol) and Fmoc-D-lysine(Boc)OH (151 mg, 0.32 
mmol) to afford 17 (202 mg, 0.19 mmol, 59%) as a white solid. Mp 116 oC. 1H NMR 
(CDCl3, 300 MHz):  7.72 (d, J = 7.8 Hz, 2H, ArH1”” and ArH8””); 7.55 (d, J = 7.8 Hz, 
2H, ArH4”” and ArH5””); 7.45 (m, 1H, NH); 7.29 (m, 11H, ArH); 6.25 (m, 3H, NH); 
5.64 (m, 1H, H2’); 5.03 (m, 4H, ArCH2, H3’); 4.59 (m, 1H, H2); 4.51 (m, 1H, H5); 4.29 
(m, 1H, H8); 4.20 (m, 2H, OCH2-H9””); 3.98 (m, 1H, H9””); 3.18 (m, 2H, H3”); 3.05 
(m, 2H, H12); 2.55 (s, 3H, 7”’-CH3); 2.52 (s, 3H, 5”’-CH3); 2.50 (m, 4H, H4”’ and H1’); 
2.03 (s, 3H, 8”’-CH3); 1.95 (m, 4H, H1” and H9); 1.74 (m, 2H, H3”’); 1.67 (m, 4H, H2” 
and H10); 1.59 (m, 2H, H11); 1.41 (s, 6H, 2 x 2”’-CH3).
 13C NMR (CDCl3, 75 MHz):  
173.0, C1; 171.7, C4; 170.7, C7; 156.8, ArC6”’; 156.2, NCO2; 153.5, NCO2; 144.0, CN3; 
143.5, ArC8a”” and ArC9a””; 141.1, ArC4a”” and ArC4b””; 135.3, ArC7”’; 135.2, 
ArC5”’; 134.8, C2’; 128.4, ArC; 128.2, ArC; 128.1, ArC; 127.5, ArC; 126.9, ArCH2”” 
and ArCH7””; 125.2, ArCH3”” and ArCH6””; 125.0, ArCH4”” and ArCH5””; 124.0, 
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ArC8”’; 119.8, ArC1”” and ArC8””; 118.9, C3’; 117.9, ArC4a”’; 79.0, C(CH3)3; 73.5, 
C2”’; 67.2, CH2-C9””; 67.0, ArCH2; 55.4, C5; 53.0, C2; 52.0, C8; 46.7, C9””; 40.6, C3”; 
39.9, C12; 35.8, C1’; 32.5, C3”’; 31.8, C2”; 29.4, C9; 28.3, C(CH3)3; 26.6, C10; 25.3, 
2”’-CH3; 22.6, C11; 21.2, C4”’; 17.5, C7”’-CH3; 15.2, C5”’-CH3; 12.0, C8”’-CH3. Mass 
Spectrum (ESI+) m/z 1078 (10%) [MH+]; 288 (100%). HRMS calcd for C58H76N7O11S 






The title compound was synthesized using the general N-Fmoc deprotection procedure 
(Procedure C), from 17 (202 mg, 0.19 mmol) to yield 18 (157 mg, 0.18 mmol, 93%) as a 
cream oil. 1H NMR (CDCl3, 300 MHz):  8.00 (d, J = 7.2 Hz, 1H, NH); 7.58 (d, J = 7.2 
Hz, 1H, NH); 7.32 (m, 5H, ArH); 6.44 (m, 3H, NH); 5.63 (m, 1H, H2’); 5.09 (m, 4H, 
ArCH2 and H3’); 4.61 (m, 2H, H2 and H5); 3.36 (m, 1H, H8); 3.22 (m, 2H, H3”); 3.05 
(m, 2H, H12); 2.62 (m, 2H, H4”’); 2.58 (s, 3H, 7”’-CH3); 2.56 (s, 3H, 5”’-CH3); 2.47 (m, 
2H, H1’); 2.15 (m, 2H, H1”); 2.10 (s, 3H, 8”’-CH3); 1.89 (m, 2H, H9); 1.80 (t, J = 6.3 
Hz, H3”’); 1.72 (m, 4H, H2” and H10); 1.58 (m, 4H, H11 and NH2); 1.42 (s, 9H, 
C(CH3)3); 1.31 (s, 6H, 2 x 2”’-CH3).
 13C NMR (CDCl3, 75 MHz):  175.7, C1; 171.6, C4; 
171.3, C7; 156.2, ArC6”’and NCO2; 153.4, ArC8”’; 135.2, ArC7”’; 135.1, ArC5”’;  
133.3, ArC; 132.2, C2’; 128.4, ArC; 128.2, ArC; 128.0, ArC; 123.8, ArC8”’; 118.9, C3’; 
117.8, ArC4a”’; 78.9, C(CH3)3; 73.5, C2”’; 66.9, ArCH2; 54.8, C8; 53.3, C2; 51.8, C5; 
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40.3, C3”; 40.0, C12; 35.9, C1’; 34.5, C2”; 32.6, C4”’; 29.6, C9; 28.3, C(CH3)3; 26.6, 
2”’-CH3; 25.4, C10; 22.6, C11; 21.3, C4”’; 18.4, 7”’-CH3; 17.4, 5”’-CH3; 15.3, C1”; 
12.0, 8”’-CH3. Mass Spectrum (ESI+) m/z 856 (100%) [MH
+]. HRMS calcd for 




The title compound was synthesised using the general peptide coupling procedure 
(Procedure B), from 10 (35 mg, 0.098 mmol) and 7a (20 mg, 0.052 mmol) to afford the 
title compound (22 mg, 0.030 mmol, 59%) as a cream solid. Mp 128 oC. 1H NMR 
(CDCl3, 300 MHz):  8.49 (s, 1H, ArH10””); 8.04 (d, J = 8.7 Hz, 2H, ArH2”’ and 
ArH6”’); 7.64 (d, J = 8.4 Hz, 2H, ArH3”’ and ArH5”’); 7.38 (m, 8H, ArH””); 6.72 (d, J 
= 7.2 Hz, 1H, NH); 6.48 (d, J = 7.2 Hz, 1H, NH); 6.37 (bs, 1H, NH); 5.59 (m, 1H, H2’); 
5.06 (m, 2H, H3’); 4.82 (m, 1H, H8); 4.60 (dd, J = 6.9, 14.1 Hz, 1H, H2); 4.45 (m, 1H, 
H5); 3.73 (s, 3H, OCH3); 3.24 (m, 2H, ArCH2); 3.08 (m, 2H, H4”); 2.47 (m, 2H, H1’); 
2.07 (s, 3H, H11); 1.93 (m, 2H, H1”); 1.68 (m, 2H, H3”); 1.50 (m, 2H, H2”); 1.44 (s, 9H, 
C(CH3)3).
 13C NMR (CDCl3, 75 MHz):  171.9, OCH3; 171.3, C4; 171.1, C10; 170.4, C7; 
156.2, NCOOC; 137.3, ArC9”; 136.5, ArC4”’; 135.7, ArC1”’; 131.9, ArC8a””; 131.4, 
ArC9a””; 131.3, C2’; 130.1, ArCH2”” and ArCH7””; 129.2, ArCH4”” and ArCH6””; 
129.1, ArCH2”’ and ArCH6”’; 128.3, ArCH3”’ and ArCH5”’; 126.8, ArCH10””; 126.5, 
ArCH4a”” and ArC10a””; 125.3, ArCH8”” and ArCH1””; 123.4, ArCH3”” and 
ArCH6””; 119.2, C3’; 79.0, C(CH3)3; 54.4, C8; 52.9, OCH3; 52.4, C2; 51.8, C5; 40.0, 
C4”; 38.2, ArCH2; 36.1, C1’; 32.2, C1”; 29.7, C3”; 29.3, C2”; 28.4, C(CH3)3; 23.1, C11. 
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Mass Spectrum (ESI+) m/z 745 (50%) [MNa+], 723 (20%) [MH+], 623 (100%) [M-Boc]. 




The title compound was synthesised using the general peptide coupling procedure 
(Procedure B), from 10 (28 mg, 0.078 mmol) and 7b (15 mg, 0.039 mmol) to afford 11b 
(14 mg, 0.019 mmol, 50%) as a cream solid. Mp 132-134 oC. 1H NMR (CDCl3, 300 
MHz):  8.76 (d, J = 8.1 Hz, 1H, ArH4””); 8.71 (d, J = 8.4 Hz, 1H, ArH3””); 7.88 (m, 
2H, ArH1”” and ArH10””); 7.60 (m, 5H, ArH7””, ArH6””, ArH5””, ArH2”” and 
ArH1””); 7.45 (d, J = 7.8 Hz, 2H, ArH2”’ and ArH6”’); 7.33 (d, J = 7.8 Hz, 2H, ArH3”’ 
and ArH5”’); 7.10 (d, J = 8.4 Hz, 1H, NH); 6.94 (d, J = 8.7 Hz, 1H, NH); 6.74 (d, J = 8.1 
Hz, 1H, NH); 5.61 (m, 1H, H2’); 5.06 (m, 2H, H3’); 4.90 (m, 1H, H8); 4.57 (m, 2H, H2 
and H5); 3.72 (s, 3H, OCH3); 3.20 (m, 2H, ArCH2); 3.08 (m, 2H, H4”); 2.47 (m, 2H, 
H1’); 2.04 (s, 3H, H11); 1.92 (m, 2H, H1”); 1.68 (m, 2H, H3”); 1.48 (m, 2H, H2”); 1.42 
(s, 9H, C(CH3)3).
 13C NMR (CDCl3, 75 MHz):  171.9, OCH3; 171.4, C4; 171.0, C10; 
170.4, C7; 156.1, NCOOC; 139.4, ArC4”’; 138.3, ArC1”’; 135.6, ArC9””; 132.0, 
ArC4b””; 131.5, ArC8a””; 131.0, ArC4a””; 130.6, ArC10a””; 130.2, ArCH2”’ and 
ArCH6”’; 129.9, ArCH3”’ and ArCH5”’; 129.2, ArCH1””; 128.6, ArCH3””; 127.5, 
ArCH6””; 126.8, ArCH1””; 126.6, ArCH5””; 126.5, ArCH10””; 122.8, ArCH2””; 122.5, 
ArCH4””; 119.3, ArCH3””; 79.1, C(CH3)3; 54.4, C8; 52.9, OCH3; 52.4, C2; 51.8, C5; 
40.0, C4”; 38.0, ArCH2; 36.1, C1’; 32.1, C1”; 29.7, C3”; 29.3, C2”; 28.4, C(CH3)3; 23.1, 
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C11. Mass Spectrum (ESI+) m/z 745 (60%) [MNa+], 723 (20%) [MH+], 623 (100%) [M-
Boc]. HRMS calcd for C42H51N4O7 723.3758, found 723.3767. 
 
4.2.20. Methyl (2S,5S,8S)-2-allyl-5-(4-aminobutyl)-8-(4-[9-anthrecenyl]benzyl)-3,6,9-
triaza-5-butylamino-4,7,10-trioxoundecanoate hydrochloride 12a 
The title compound was synthesized using the general N-Boc deprotection procedure 
(Procedure A), from 11a (20 mg, 0.028 mmol) to yield 12a (13 mg, 0.017 mmol, 61%) as 
a light yellow solid. Mp 194-202 oC. 1H NMR (CD3OD, 300 MHz):  8.53 (s, 1H, 
ArH10””); 8.26 (m, 3H, exchanging NH’s); 8.06 (d, J = 8.1 Hz, 2H, ArH2”’ and 
ArH6”’); 7.64 (d, J = 9.0 Hz, 2H, ArH3”’ and ArH5”’); 7.38 (m, 8H, ArH””); 5.68 (m, 
1H, H2’); 5.02 (m, 2H, H3’); 4.67 (m, 1H, H8); 4.45 (m, 2H, H2 and H5); 3.69 (s, 3H, 
OCH3); 2.93 (m, 4H, H4” and ArCH2); 2.44 (m, 2H, H1’); 2.00 (s, 3H, H11); 1.69 (m, 
4H, H1” and H3”); 1.50 (m, 2H, H2”). 13C NMR (CD3OD, 75 MHz):  174.4, C7; 173.7, 
C1; 173.6, C4; 173.5, C10; 138.7, ArC4”’; 137.8, ArC1”’; 137.7, ArC9””; 134.1, C2’; 
132.9, ArCH2”’ and ArCH6”’; 132.4, ArC4a”” and ArC10a””; 131.5, ArC8a”” and 
ArC9a””; 130.4, ArCH4”” and ArCH5””; 130.1, ArCH3”’ and ArCH5”’; 129.5, 
ArCH10””; 127.7, ArCH8”” and ArCH1””; 126.5, ArCH2”” and ArCH7””; 126.2, 
ArCH3”” and ArCH6””; 118.8, C3’; 56.7, C5; 53.8, OCH3; 53.6, C8; 52.7, C2; 40.5, 
C4”; 38.6, ArCH2; 36.6, C1’; 32.8, C1”; 28.1, C3”; 23.4, C11; 22.4, C2”. Mass Spectrum 
(ESI+) m/z 623 (100%) [M+]. HRMS calcd for C37H43N4O5 623.3233, found 623.3215. 
 
4.2.21. Methyl (2S,5S,8S)-2-allyl-5-(4-aminobutyl)-3,6,9-triaza-5-butylamino-4,7,10-
trioxo-8-(4-[9-[phenanthrenyl]benzyl)undecanoate hydrochloride 12b 
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The title compound was synthesized using the general N-Boc deprotection procedure 
(Procedure A), from 11b (24 mg, 0.033 mmol) to yield 12b (15 mg, 0.023 mmol, 69%) as 
a light yellow solid. Mp 198 oC. 1H NMR (CD3OD, 300 MHz):  8.84 (d, J = 7.8 Hz, 1H, 
ArH4””); 8.78 (d, J = 8.1 Hz, 1H, ArH5””); 8.30 (d, J = 7.2 Hz, 1H, exchanging NH); 
8.15 (d, J = 8.1 Hz, 1H, exchanging NH); 7.90 (m, 2H, ArH1”” and ArH10””); 7.60 (m, 
5H, ArH7””, ArH6””, ArH5””, ArH2”” and ArH1””); 7.45 (d, J = 8.4 Hz, 2H, ArH2”’ 
and ArH6”’); 7.40 (d, J = 8.7 Hz, 2H, ArH3”’ and ArH5”’); 5.68 (m, 1H, H2’); 4.98 (m, 
2H, H3’); 4.61 (m, 1H, H8); 4.40 (m, 2H, H2 and H5); 3.67 (s, 3H, OCH3); 2.93 (t, J = 
7.5 Hz, 2H, H4”); 2.40 (m, 2H, H1’); 1.99 (s, 3H, H11); 1.83 (m, 4H, H1” and ArCH2); 
1.69 (m, 2H, H3”); 1.49 (m, 2H, H2”). ). 13C NMR (CD3OD, 75 MHz):  173.7, C7; 
173.6, C1; 173.5, C4; 173.4, C10; 140.7, ArC4”’; 139.8, ArC1”’; 137.5, ArC9””; 134.0, 
C2’; 133.0, ArC8a””; 132.3, ArC4b””; 132.0, ArC4a””; 131.3, ArCH2”’ and ArCH6”’; 
131.2, ArC10a””; 130.3, ArCH3”’ and ArCH5”’; 129.7, ArCH1””; 128.5, ArCH7””; 
128.0, ArCH6””; 127.9, ArCH1””; 127.8, ArCH5””; 127.7, ArCH10””; 127.6, ArCH2””; 
124.2, ArC4””; 124.1, ArCH3””; 118.8, C3’; 56.7, C5; 53.7, OCH3; 53.6, C8; 52.7, C2; 
40.5, C4”; 38.5, ArCH2; 36.5, C1’; 32.8, C1”; 28.0, C3”; 23.3, C11; 22.4, C2”. Mass 







The title compound was synthesised using the general peptide coupling procedure 
(Procedure B), from 18 (40 mg, 0.045 mmol) and 7a (17 mg, 0.045 mmol) to afford 19a 
(20 mg, 0.016 mmol, 36%) as a white solid. Mp 108-110 oC. 1H NMR (CDCl3, 300 
MHz):  8.48 (s, 1H, ArH10””’); 8.03 (m, 2H, ArH); 7.58 (m, 2H, ArH); 7.44 (m, 2H, 
ArH); 7.30 (m, 11H, ArH); 6.82 (bs, 1H, NH); 6.36 (bs, 2H, NH2); 5.77 (m, 1H, H2’); 
5.12 (m, 4H, H3’ and PhCH2O); 4.85 (m, 1H, H11); 4.59 (m, 1H, H2); 4.44 (m, 1H, H5); 
4.31 (m, 1H, H8); 3.19 (m, 2H, 11-CH2); 2.95 (m, 4H, H4”” and H3”); 2.56 (s, 3H, 7”’-
CH3); 2.54 (s, 3H, 5”’-CH3); 2.52 (m, 4H, H4”’ and H1’); 2.06 (s, 3H, 8”’-CH3); 1.97 (m, 
2H, H3””); 1.94 (s, 3H, H14); 1.74 (m, 4H, H1” and H1””); 1.71 (m, 2H, H3”’); 1.62 (m, 
2H, H2”); 1.38 (m, 2H, H2””); 1.36 (s, 9H, C(CH3)3); 1.23 (s, 6H, 2 x 2”’-CH3).
 13C 
NMR (CDCl3, 75 MHz):  173.0, C13; 172.2, C1; 172.0, C4; 171.8, C7; 170.6, C10; 
156.3, ArC6”’; 156.2, NCO2; 153.6, ArC8a”’; 142.8, CN3; 140.0, ArC; 139.9, ArC; 
136.5, ArC7”’; 135.4, ArC5”’; 133.2 ArC; 132.5, C2’; 131.5, ArC; 131.3, 2 x ArCH; 
130.1, ArCH; 129.2, ArCH; 128.1, ArCH; 127.9, ArCH; 127.6, ArCH; 127.5, ArCH; 
126.6, ArC; 125.3, ArCH; 125.1, ArCH; 124.1, ArC; 123.5, ArC8”’; 119.0, C3’; 118.0, 
ArC4a”’; 79.0, C(CH3)3; 73.7, C2”’; 67.0, CH2-ester; 57.7, C11; 54.6, C2; 53.2, C5; 52.3, 
C8; 40.7, C3”; 39.8, C4””; 37.5, C1’; 36.0, C2”; 32.7, C4”’; 29.7, C1””; 29.3, 11-CH2; 
28.4, C(CH3)3; 27.1, C1”; 26.7, 2”’-CH3; 25.3, C2””; 22.9, C14; 22.8, C3””; 21.4, C3”’; 
18.6, 7”’-CH3; 17.5, 5”’-CH3; 12.1, 8”’-CH3. Mass Spectrum (ESI+) m/z 1221 (10%) 







The title compound was synthesised using the general peptide coupling procedure 
(Procedure B), from 18 (38 mg, 0.044 mmol) and 7b (16 mg, 0.042 mmol) to afford 19b 
(41 mg, 0.034 mmol, 80%) as a white solid. Mp 108 oC. 1H NMR (CDCl3, 300 MHz):  
8.72 (m, 2H, ArH); 7.58 (m, 16H, ArH); 6.40 (bs, 2H, NH); 5.71 (m, 1H, H2’); 5.13 (m, 
2H, PhCH2O); 5.03 (m, 2H, H3’); 4.83 (m, 1H, H11); 4.60 (m, 1H, H2); 4.59 (m, 1H, 
H5); 4.29 (m, 1H, H8); 3.12 (m, 2H, 11-CH2); 2.94 (m, 4H, H4”” and H3”); 2.56 (s, 3H, 
7”’-CH3); 2.54 (s, 3H, 5”’-CH3); 2.53 (m, 4H, H4”’ and H1’); 2.07 (s, 3H, 8”’-CH3); 1.91 
(s, 3H, H14); 1.82 (m, 4H, H1” and H1””); 1.72 (t, J = 6.6 Hz, 2H, H3”’); 1.62 (m, 4H, 
H2” and H3””); 1.39 (m, 2H, H2””); 1.34 (s, 9H, C(CH3)3); 1.23 (s, 6H, 2 x 2”’-CH3).
 13C 
NMR (CDCl3, 75 MHz):  173.0, C13; 172.4, C1; 172.0, 171.9, C10; C4; 171.7, C7; 
156.3, ArC6”’; 156.1, NCO2; 153.6, CN3; 139.3, ArC8a”’; 138.2, ArC; 135.3, ArC and 
ArC7”’; 134.7, ArC5”’; 133.2, C2’; 132.7, ArC; 132.5, ArC; 131.4, ArC; 130.8, ArC; 
130.6, ArCH; 130.2, ArCH; 129.8, ArC; 129.2, ArC; 128.6, ArCH; 128.5, ArCH; 128.3, 
ArCH; 128.1, ArCH; 127.4, ArCH; 126.8, ArCH; 126.6, 2 x ArCH; 126.4, ArCH; 126.2, 
ArCH; 124.0, ArCH; 122.9, ArC8”’; 122.4, ArCH; 118.9, C3’; 118.0, ArC4a”’; 78.9, 
C(CH3)3; 73.6, C2”’; 66.9, CH2-ester; 55.4, C11; 54.5, C8; 53.2, C5; 52.2, C2; 40.6, C3”; 
39.8, C4””; 37.6, 11-CH2; 36.0, C4”’; 32.6, H1’; 30.6, H1”; 29.6, C1””; 29.4, H14; 28.3, 
C(CH3)3; 26.7, 2”’-CH3; 25.4, C2”; 22.9, C3””; 22.8, C2””; 21.5, 7”’-CH3; 18.6, 5”’-
CH3; 17.5, C3”’; 12.1, 8”’-CH3. Mass Spectrum (ESI+) m/z 1221 (100%) [MH
+]. HRMS 






The title compound was synthesised using the general peptide coupling procedure 
(Procedure B), from N-acetyl-O-allyl-L-tyrosine17 (60 mg, 0.069 mmol) and 16 (18 mg, 
0.068 mmol) to afford the 19c (65 mg, 0.058 mmol, 85%) as a white solid. Mp 94-102 
oC. 1H NMR (CDCl3, 300 MHz):  7.76 (bs, 1H, NH); 7.54 (bs, 1H, NH); 7.41 (bs, 1H, 
NH); 7.31 (m, 5H, ArH); 7.09 (d, J = 8.7 Hz, 2H, ArH2””’ and ArH6””’); 6.77 (d, J = 8.4 
Hz, 2H, ArH3””’ and ArH5””’); 6.39 (bs, 3H, 3 x NH); 6.02 (m, 1H, H2”””); 5.70 (m, 
1H, H2’); 5.39 (dd, J = 1.5, 17.1 Hz, 1H, H3a”””); 5.26 (dd, J = 1.2, 10.5 Hz, 1H, 
H3b”””); 5.06 (m, 2H, H3’); 5.05 (m, 2H, PhCH2O); 4.65 (dd, J = 6.9, 13.5 Hz, 1H, 
H11); 4.57 (dd, J = 8.1, 13.5 Hz, 1H, H2); 4.50 (m, 1H, H5); 4.45 (d, J = 5.4 Hz, 2H, 
H1”””); 4.41 (m, 1H, H8); 4.14 (bs, 1H, NH); 3.15 (m, 2H, H3”); 2.92 (m, 4H, H4”” and 
11-CH2); 2.58 (m, 4H, H1’ and H4”’); 2.53 (s, 3H, 7”’-CH3); 2.52 (s, 3H, 5”’-CH3); 2.08 
(s, 3H, H14); 1.94 (m, 4H, H1” and H1””); 1.84 (s, 3H, 8”’-CH3); 1.78 (m, 2H, H3”’); 
1.69 (m, 4H, H2” and H2””); 1.55 (m, 2H, H3””); 1.40 (s, 9H, C(CH3)3); 1.30 (s, 6H, 2 x 
2”’-CH3).
 13C NMR (CDCl3, 75 MHz):  172.2, C1; 172.0, C4; 171.6, C7; 157.5, C10; 
156.2, C13 and NCO2; 156.1, ArC6”’; 153.5, ArC8a”’; 135.3, ArC7”’; 134.7, ArC5”’; 
133.1, C2”””; 132.5, C2’; 130.5, ArC4””’, 130.2, ArCH2””’ and ArCH6””’; 128.5, 
ArC1””’; 128.4, ArCH; 128.3, ArCH; 128.2, ArCH; 128.1, ArC; 124.0, ArC8”’; 118.8, 
C3’; 118.0, C3”””; 117.6, ArC4a”’; 114.7, ArCH3””’ and ArCH5””’; 78.9, C(CH3)3; 
73.7, C2”’; 68.7, C1”””; 66.9, ArCH2; 55.6, C11; 54.5, C5; 53.1, C8; 52.2, C2; 41.2, C3”; 
40.0, C4””; 37.2, 11-CH2; 35.9, C1’; 34.0, C4”’; 32.7, C2””; 31.1, C2’; 29.4, C1””; 28.4, 
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C(CH3)3; 26.7, 2”’-CH3; 22.9, C3””; 22.6, C14; 21.4, C3”’; 18.5, 7”’-CH3; 17.5, 5”’-CH3; 
12.1, 8”’-CH3. Mass Spectrum (ESI+) m/z 1101 (30%) [MH
+]; 288 (100%). HRMS calcd 




The title compound was synthesized using the general N-Boc deprotection procedure 
(Procedure A), from 19a (20 mg, 0.016 mmol) to yield 20a (13 mg, 0.014mmol, 88%) as 
a white solid. Mp 218-220 oC. 1H NMR (CD3OD, 300 MHz):  7.68 (m, 17H, ArH); 5.77 
(m, 1H, H2’); 5.15 (m, 4H, H3’ and PhCH2O); 4.82 (m, 1H, H11); 4.42 (m, 1H, H2); 
4.25 (m, 1H, H5); 4.07 (m, 1H, H8); 3.18 (m, 2H, 11-CH2); 2.88 (m, 4H, H4”” and H3”); 
2.55  (m, 2H, H1’); 1.95 (s, 3H, H14); 1.85 (m, 2H, H1”); 1.65 (m, 2H, H1”’); 1.53 (m, 
2H, H2”); 0.94 (m, 2H, H2”’). 13C NMR (CD3OD, 75 MHz):  175.2, C13; 174.4, C1; 
174.2, C4; 174.1, C10; 172.5, C7; 158.6, CN3; 140.0, ArC; 139.9, ArC; 138.1, ArC; 
137.4, ArC; 134.3, C2’; 133.2, ArC; 131.5, ArC; 131.3, ArCH; 130.1, ArCH; 129.2, ArC; 
128.1, ArC; 127.9, ArCH; 127.6, ArCH; 127.5, ArCH; 126.6, ArCH; 125.9, ArCH; 
125.8, ArCH; 125.6, ArCH; 124.2, ArCH; 119.1, C3’; 68.1, CH2-ester; 57.9, C11; 55.3, 
C8; 54.7, C5; 54.2, C2; 42.1, C3”; 40.3, C4”’; 38.1, 11-CH2; 36.7, C1’; 31.4, C1”: 29.4, 
C1”’; 27.3, C14; 26.5, C2”; 23.6, C3”’; 22.5, C2”’. Mass Spectrum (ESI+) m/z 855 





The title compound was synthesized using the general N-Boc deprotection procedure 
(Procedure A), from 19b (42 mg, 0.034 mmol) to yield 20b (25 mg, 0.027 mmol, 79%) as 
a white solid. Mp 215-220 oC. 1H NMR (CD3OD, 300 MHz):  8.82 (m, 2H, ArH); 7.60 
(m, 16H, ArH); 5.81 (m, 1H, H2’); 5.15 (m, 4H, PhCH2O and H3’); 4.58 (m, 1H, H11); 
4.43 (m, 1H, H2); 4.35 (dd, J = 4.8, 9.0 Hz, 1H, H5); 4.17 (dd, J = 4.8, 9.6 Hz, 1H, H8); 
3.17 (m, 4H, H4”” and H3”); 2.72 (m, 2H, 11-ArCH2); 2.59 (m, 1H, H1’); 1.96 (s, 3H, 
H14); 1.80 (m, 4H, H1” and H1”’); 1.65 (m, 2H, H3”’); 1.51 (m, 2H, H2”); 1.22 (m, 2H, 
H2”’). 13C NMR (CD3OD, 75 MHz):  175.2, C13; 174.4, C1; 174.2, C4; 174.1, C10; 
172.5, C7; 158.6, CN3; 140.7, ArC; 139.6, ArC; 137.4, ArC; 137.2, ArC; 134.3, C2’; 
132.9, ArC; 132.1, ArC; 131.3, ArCH; 130.5, ArCH; 129.7, ArC; 129.6, ArC; 129.4, 2 x 
ArCH; 128.5, ArCH; 128.1, ArCH; 127.9, ArCH; 127.8, ArCH; 127.6, ArCH; 124.2, 
ArCH; 123.7, ArCH; 12.4, ArCH; 122.1, ArCH; 121.8, ArCH; 119.0, C3’; 68.0, CH2-
ester; 57.7, C11; 55.2, C8; 54.7, C5; 54.0, C2; 42.0, C3”; 40.1, C4”’; 38.1, 11-CH2; 36.6, 
C1’; 31.3, C1”: 29.6, C1”’; 27.8, C14; 26.4, C2”; 23.8, C3”’; 22.6, C2”’. Mass Spectrum 
(ESI+) m/z 855 (30%) [M2+], 428 (100%). HRMS calcd for C49H59N8O6 855.4558, found 
855.4528. 
4.2.27. Benzyl (2S,5R,8R,11S)-2-allyl-11-(4-allyloxybenzyl)-8-(4-aminobutyl)-3,6,9,12-
tetraaza-5-(3-[guanidino]propyl)-4,7,10,13-tetraoxotetradecanoate hydrochloride 20c 
The title compound was synthesized using the general N-Boc deprotection procedure 
(Procedure A), from 19c (65 mg, 0.059 mmol) to yield 20c (39 mg, 0.048 mmol, 82%) as 
a cream solid. Mp 108oC. 1H NMR (CDCl3, 300 MHz):  7.35 (m, 5H, ArH); 7.16 (d, J = 
8.7 Hz, 2H, ArH2”’ and ArH6”’); 6.87 (d, J = 8.7 Hz, 2H, ArH3”’ and ArH5”’); 6.02 (m, 
1H, H2”’); 5.78 (m, 1H, H2’); 5.39 (dd, J = 1.8, 17.1 Hz, 1H, H3a””’); 5.24 (dd, J = 1.8, 
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10.5 Hz, 1H, H3b””’); 5.10 (m, 4H, H3’ and PhCH2O); 4.52 (m, 2H, H1””’); 4.39 (m, 2H, 
H13 and H2); 4.24 (dd, J = 4.8, 9.0 Hz, 1H, H5); 3.98 (dd, J = 3.9, 9.9 Hz, 1H, H8); 3.16 
(m, 2H, H3”); 2.94 (m, 2H, 11-CH2); 2.84 (m, 2H, H4”’); 2.55 (m, 2H, H1’); 1.94 (s, 3H, 
H14); 1.87 (m, 2H, H1”); 1.73 (m, 2H, H1”’); 1.54 (m, 4H, H2” and H2”’); 1.03 (m, 2H, 
H3”’). 13C NMR (CDCl3, 75 MHz):  175.4, C1; 174.4, C4; 174.2, C7; 172.5, C10; 159.0, 
C13; 158.5, NCO; 137.2, ArC4””; 134.9, C2””’; 134.3, C2’; 131.5, ArC; 130.0, ArCH2”” 
and ArCH6””; 129.6, ArCH; 129.4, ArCH; 129.4, ArCH; 128.5, ArC1”; 119.0, C3’; 
117.6, C3””’; 115.9, ArCH3”’ and ArCH5”’; 69.8, C1””’; 67.9, CH2-ester); 57.8, C11; 
55.3, C5; 54.8, C8; 54.0, C2; 41.9, C3”; 40.3, C4”’; 37.4, 11-CH2; 36.5, C1’; 31.2, C1”’; 
29.5, C2”; 28.0, C2”’; 26.5, C14; 23.8, C3”’; 22.5, C1”. Mass Spectrum (ESI+) m/z 735 
[M2+] (70%), 368 (100%). HRMS calcd for C38H55N8O7 735.4194, found 735.4200. 
 
4.3. In vitro antimicrobial activity 
Antibacterial testing against Staphylococcus aureus ATCC6538P was performed at 
Avexa Corporation, Melbourne, Australia. Assay procedure: A standardised inoculate for 
assays was prepared in 1/10 dilution of seed culture. To a 96 well microtitre plate was 
added 50 μL of liquid medium [Mueller-Hinton broth medium (MHB) and Mueller-
Hinton agar medium (MHA)]. The peptoid compounds were dissolved in a 50% 
MeOH/H2O solution for the final concentration of 1 mg/mL. Test solution (50 μL) was 
added into the top row of the plate. A dilution series was continued until it reached the 
last row of the plate the excess was discarded. The plates (2 peptoid samples were tested 
per plate) were incubated at 37 °C and shaken at 100 rpm for 18 h. 
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